Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 3634948, 10 pages
Review Article

Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders

1Department of Internal Medicine, Occupational Diseases Hypertension and Clinical Oncology, Wroclaw Medical University, Ulica Borowska 213, 50-556 Wrocław, Poland
2Research and Development Department, Integrated Cardiovascular Centre Provincial Specialist Hospital in Wroclaw (WROVASC), Ulica Kamieńskiego 73a, 51-124 Wrocław, Poland

Received 13 March 2016; Accepted 12 May 2016

Academic Editor: Carlos Rosales

Copyright © 2016 A. Janus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Insulin resistance and other risk factors for atherosclerosis, such as hypertension and hypercholesterolemia, promote endothelial dysfunction and lead to development of metabolic syndrome which constitutes an introduction to cardiovascular disease. The insulin resistance and endothelial dysfunction cross talk between each other by numerous metabolic pathways. Hence, targeting one of these pathologies with pleiotropic treatment exerts beneficial effect on another one. Combined and expletive treatment of hypertension, lipid disorders, and insulin resistance with nonpharmacological interventions and conventional pharmacotherapy may inhibit the transformation of metabolic disturbances to fully developed cardiovascular disease. This paper summarises the common therapeutic targets for insulin resistance, endothelial dysfunction, and vascular inflammatory reaction at molecular level and analyses the potential pleiotropic effects of drugs used currently in management of cardiovascular disease, metabolic syndrome, and diabetes.